• ClipSaver
ClipSaver
Русские видео
  • Смешные видео
  • Приколы
  • Обзоры
  • Новости
  • Тесты
  • Спорт
  • Любовь
  • Музыка
  • Разное
Сейчас в тренде
  • Фейгин лайф
  • Три кота
  • Самвел адамян
  • А4 ютуб
  • скачать бит
  • гитара с нуля
Иностранные видео
  • Funny Babies
  • Funny Sports
  • Funny Animals
  • Funny Pranks
  • Funny Magic
  • Funny Vines
  • Funny Virals
  • Funny K-Pop

MediWound Q1 2025: Supply, Trials, Stockpiles скачать в хорошем качестве

MediWound Q1 2025: Supply, Trials, Stockpiles 4 месяца назад

скачать видео

скачать mp3

скачать mp4

поделиться

телефон с камерой

телефон с видео

бесплатно

загрузить,

Не удается загрузить Youtube-плеер. Проверьте блокировку Youtube в вашей сети.
Повторяем попытку...
MediWound Q1 2025: Supply, Trials, Stockpiles
  • Поделиться ВК
  • Поделиться в ОК
  •  
  •  


Скачать видео с ютуб по ссылке или смотреть без блокировок на сайте: MediWound Q1 2025: Supply, Trials, Stockpiles в качестве 4k

У нас вы можете посмотреть бесплатно MediWound Q1 2025: Supply, Trials, Stockpiles или скачать в максимальном доступном качестве, видео которое было загружено на ютуб. Для загрузки выберите вариант из формы ниже:

  • Информация по загрузке:

Скачать mp3 с ютуба отдельным файлом. Бесплатный рингтон MediWound Q1 2025: Supply, Trials, Stockpiles в формате MP3:


Если кнопки скачивания не загрузились НАЖМИТЕ ЗДЕСЬ или обновите страницу
Если возникают проблемы со скачиванием видео, пожалуйста напишите в поддержку по адресу внизу страницы.
Спасибо за использование сервиса ClipSaver.ru



MediWound Q1 2025: Supply, Trials, Stockpiles

Welcome to the TalkTickers Deep Dive into MediWound Ltd.'s (MDWD) Q1 2025 earnings call. We cut through the noise to bring you the essentials. Financially, Q1 saw total revenue decrease to $4 million from $5 million year-over-year, primarily due to lower Barta-funded development services revenue as programs near completion. Despite this, gross profit slightly increased to $4.7 million from $4.6 million, driven by an improved gross margin (19% vs. 12%) from a favorable revenue mix. Operating expenses rose significantly, with R&D nearly doubling to $2.9 million due to investment in the Eskerax Phase 3 trial and related activities, while SG&A saw a slight increase. This resulted in a wider operating loss of $5.2 million compared to $3.7 million in Q1 2024. However, net loss improved substantially to $0.07 per share from $0.15 per share, primarily due to non-cash financial income from warrant revaluation, highlighting the impact of accounting items below the operating line. The company ended the quarter with $38.7 million in cash, having used approximately $5.1 million in operations. Key pipeline updates include steady progress for Eskerax, their enzymatic debrider for chronic wounds. The large Phase 3 VALUE study for venous leg ulcers (VLUs) is on track, with global site activation progressing. Management plans an interim analysis around mid-2026 when 65% enrollment is reached. A smaller Phase 2 head-to-head study comparing Eskerax to collagenase (Santyl) is planned for the second half of 2025 to provide comparative data crucial for market access and pricing, potentially finishing before Phase 3 results. The diabetic foot ulcer (DFU) program is moving forward, partly funded by a European Innovation Council (EIC) grant, with a trial planned for a 2026 start following regulatory protocol finalization. Compelling Phase 2 DFU data showed significantly faster and more complete debridement and granulation tissue formation compared to vehicle gel. MediWound is also collaborating with leading wound care companies like Carassus, which they view as strong external validation. For Nexobrid, the burn therapy, US launch continues with consistent ordering from nearly 60 burn centers, and partner Varysel reported strong Q1 growth. Global demand, however, continues to outstrip manufacturing capacity, notably in Europe and Japan. The new manufacturing facility commissioning remains on track for operational readiness by the end of 2025, with commercial availability anticipated in 2026 pending regulatory approvals. Notably, data highlighting Nexobrid's use in treating blast injuries during the Israel-Hamas war has driven significant government interest globally, including from the US, in potential stockpiling and a domestic backup manufacturing site, planning for which is supported by Barta and expected to wrap up by Q3 2025. Management believes these investments and pipeline advancements position MediWound for long-term value, with key potential catalysts potentially converging around mid-2026 related to manufacturing capacity and Eskerax clinical data. AI Disclaimer: This video was generated with the help of AI. All insights are based on factual data, but the presentation may include creative commentary for engagement purposes. Financial Advice Disclaimer: The content in this video is for informational purposes only and should not be considered financial advice. Always do your own research or consult a financial advisor before making any investment decisions. Representation & Warranties Disclaimer: The content provided in this video is for entertainment purposes only. TalkTickers makes no representations or warranties regarding the accuracy, completeness, or reliability of any information presented, including but not limited to names, dates, and financial data. This video was generated with the assistance of AI models, which are known to hallucinate or provide inaccurate information. As such, material facts may be misrepresented or misstated. Always refer to official earnings reports and consult with a financial advisor before making any decisions. #aipodcast #earningscall #aipodcast

Comments

Контактный email для правообладателей: [email protected] © 2017 - 2025

Отказ от ответственности - Disclaimer Правообладателям - DMCA Условия использования сайта - TOS



Карта сайта 1 Карта сайта 2 Карта сайта 3 Карта сайта 4 Карта сайта 5